# FDA recall D-0042-2024

> **Scynexis, Inc.** · Class I · drug recall initiated 2023-09-25.

## Product

BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302  NDC 75788-115-04

## Reason for recall

Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

## Distribution

Nationwide in the US.

## Key facts

- **Recall number:** D-0042-2024
- **Recalling firm:** Scynexis, Inc.
- **Classification:** Class I
- **Product type:** drug
- **Status:** Completed
- **Initiation date:** 2023-09-25
- **Report date:** 2023-10-18

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Jersey City, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0042-2024

## Citation

> AI Analytics. FDA recall D-0042-2024. Retrieved 2026-06-25 from https://api.ai-analytics.org/recall/D-0042-2024. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*